Tandem Meetings 2023

CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT 5:15
CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
Outcomes of children and young adults with B-ALL following tisa-cel reinfusion 3:52
Outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney • 24 Feb 2023
Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL 3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Shah • 15 Feb 2023
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL 3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah • 15 Feb 2023
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma 2:47
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
Sergio Giralt • 17 Feb 2023
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML 3:48
Preliminary results from Phase I study of CD123 CAR-T therapy in pediatric R/R AML
Swati Naik • 20 Feb 2023
The content of VJRegenMed is intended for healthcare professionals